-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 UCCKbrUJYbzdH16AunAGErLkOX4jbYMJM3fYUW27vM0DhxGCQUTE5u4UEE+vQZTP
 TPGyuUbD+nmZR7L1wmsJCw==

<SEC-DOCUMENT>0000950123-09-045270.txt : 20090923
<SEC-HEADER>0000950123-09-045270.hdr.sgml : 20090923
<ACCEPTANCE-DATETIME>20090923171749
ACCESSION NUMBER:		0000950123-09-045270
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20090921
ITEM INFORMATION:		Unregistered Sales of Equity Securities
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20090923
DATE AS OF CHANGE:		20090923

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			GeoVax Labs, Inc.
		CENTRAL INDEX KEY:			0000832489
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731]
		IRS NUMBER:				870455038
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-52091
		FILM NUMBER:		091083170

	BUSINESS ADDRESS:	
		STREET 1:		1256 BRIARCLIFF ROAD N.E.
		STREET 2:		EMTECH BIO SUITE 500
		CITY:			ATLANTA
		STATE:			GA
		ZIP:			30306
		BUSINESS PHONE:		404-727-0971

	MAIL ADDRESS:	
		STREET 1:		1256 BRIARCLIFF ROAD N.E.
		STREET 2:		EMTECH BIO SUITE 500
		CITY:			ATLANTA
		STATE:			GA
		ZIP:			30306

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Geovax Labs, Inc.
		DATE OF NAME CHANGE:	20061002

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	DAUPHIN TECHNOLOGY INC
		DATE OF NAME CHANGE:	19940826

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SUCCESSO INC
		DATE OF NAME CHANGE:	19910410
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>c90419e8vk.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">



<DIV style="font-size: 10pt">
<DIV style="width: 100%; border-bottom: 2pt solid black; font-size: 1pt">&nbsp;</DIV>
<DIV style="width: 100%; border-bottom: 1pt solid black; font-size: 1pt">&nbsp;</DIV>


<P align="center" style="font-size: 14pt"><B>UNITED STATES<BR>
SECURITIES AND EXCHANGE COMMISSION<BR>
<FONT style="font-size: 12pt">Washington, D.C. 20549
</FONT></B>

<P align="center" style="font-size: 18pt"><B>FORM 8-K</B>

<P align="center" style="font-size: 12pt"><B>CURRENT REPORT<BR>
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</B>

<P align="center" style="font-size: 10pt"><B>Date of Report (Date of earliest event reported): September 21, 2009</B>

<P align="center">

<P align="center" style="font-size: 24pt"><B>GEOVAX LABS, INC.<BR></B>
<FONT style="font-size: 10pt">(Exact name of registrant as specified in its charter)
</FONT>

<TABLE border="0" width="100%" cellspacing="0" cellpadding="0" style="font-size: 10pt; text-align: center">
<TR>
    <TD width="32%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="33%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="32%">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD style="border-bottom: 1px solid #000000"><B>Delaware</B></TD>
    <TD>&nbsp;</TD>
    <TD style="border-bottom: 1px solid #000000"><B>000-52091</B></TD>
    <TD>&nbsp;</TD>
    <TD style="border-bottom: 1px solid #000000"><B>87-0455038</B></TD>
</TR>
<TR valign="top">
    <TD>(State or other Jurisdiction of Incorporation)</TD>
    <TD>&nbsp;</TD>
    <TD>(Commission File Number)</TD>
    <TD>&nbsp;</TD>
    <TD>(IRS Employer Identification No.)</TD>
</TR>
</TABLE>

<TABLE border="0" width="100%" cellspacing="0" cellpadding="0" style="font-size: 10pt; text-align: center">
<TR>
    <TD width="49%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="49%">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD style="border-bottom: 1px solid #000000"><B>1256 Briarcliff Road N.E.<BR>Emtech Bio Suite 500<BR>Atlanta, Georgia <BR></B></TD>
    <TD>&nbsp;</TD>
    <TD style="border-bottom: 1px solid #000000"><B>30306</B></TD>
</TR>
<TR valign="top">
    <TD>(Address of Principal Executive Offices)</TD>
    <TD>&nbsp;</TD>
    <TD>(Zip Code)</TD>
</TR>
</TABLE>

<P align="center" style="font-size: 10pt">Registrant&#146;s telephone number, including area code: <B>(404) 727-0971</B>


<TABLE border="0" width="30%" cellspacing="0" cellpadding="0" style="font-size: 10pt; text-align: center">
<TR>
    <TD width="100%">&nbsp;</TD>
</TR>
<TR>
    <TD nowrap style="border-bottom: 1px solid #000000"><B>&nbsp;</B></TD>
</TR>
<TR>
    <TD nowrap>(Former name or former address if changed since last report.)</TD>
</TR>
</TABLE>

<P align="left" style="font-size: 10pt">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:

<P align="left" style="font-size: 10pt">
<FONT face="Wingdings">&#111;</FONT> Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)<BR><BR>
<FONT face="Wingdings">&#111;</FONT> Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)<BR><BR>
<FONT face="Wingdings">&#111;</FONT> Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))<BR><BR>
<FONT face="Wingdings">&#111;</FONT> Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))<BR>


<P>
<DIV style="width: 100%; border-bottom: 1pt solid black; margin-top: 10pt; font-size: 1pt">&nbsp;</DIV>
<DIV style="width: 100%; border-bottom: 2pt solid black; font-size: 1pt">&nbsp;</DIV>

</DIV>

<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt; display: none">1
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">

<P align="left" style="font-size: 10pt; text-indent: 4%">This Form 8-K and other reports filed by GeoVax Labs, Inc. (the &#147;registrant&#148;) from time to time with the
Securities and Exchange Commission (collectively the &#147;Filings&#148;) contain forward looking statements and information that
are based upon beliefs of, and information currently available to, the registrant&#146;s management as well as estimates and
assumptions made by the registrant&#146;s management. When used in the Filings the words &#147;anticipate&#148;, &#147;believe&#148;,
&#147;estimate&#148;, &#147;expect&#148;, &#147;future&#148;, &#147;intend&#148;, &#147;plan&#148; or the negative if these terms and similar expressions as they relate
to the registrant or the registrant&#146;s management identify forward looking statements. Such statements reflect the
current view of the registrant with respect to future events and are subject to risks, uncertainties, assumptions and
other factors relating to the registrant&#146;s industry, operations and results of operations and any businesses that may
be acquired by the registrant. These risks include the risk that the Company may not generate revenue or achieve
profitability in the future, the Company&#146;s need for continued funding, that the products the Company has under
development may not prove successful, and other risks, including those set forth in the registrant&#146;s most recent Form
10-K and subsequent Filings. Should one or more of these risks or uncertainties materialize, or should the underlying
assumptions prove incorrect, actual results may differ significantly from those anticipated, believed, estimated,
expected, intended or planned.


<P align="left" style="font-size: 10pt"><B>Item&nbsp;3.02 Unregistered Sales of Equity Securities.</B>


<P align="left" style="font-size: 10pt; text-indent: 4%">On July&nbsp;14, 2009 we sold 467,836 shares of our common stock, $0.001 par value, to Fusion Capital Fund II, LLC
(&#147;Fusion Capital&#148;) related to a Common Stock Purchase Agreement dated May&nbsp;8, 2008 (the &#147;Purchase Agreement&#148;) for an
aggregate purchase price of $80,000. We also issued to Fusion Capital an additional 19,844 shares of our common stock
as a partial settlement of the commitment fee for entering into the Purchase Agreement.


<P align="left" style="font-size: 10pt; text-indent: 4%">On July&nbsp;27, 2009 we sold 529,801 shares of our common stock, $0.001 par value, to Fusion Capital related to the
Purchase Agreement for an aggregate purchase price of $80,000. We also issued to Fusion Capital an additional 19,844
shares of our common stock as a partial settlement of the commitment fee for entering into the Purchase Agreement.


<P align="left" style="font-size: 10pt; text-indent: 4%">On September&nbsp;4, 2009 we sold 198,413 shares of our common stock, $0.001 par value, to Fusion Capital related to
the Purchase Agreement for an aggregate purchase price of $25,000. We also issued to Fusion Capital an additional
6,201 shares of our common stock as a partial settlement of the commitment fee for entering into the Purchase
Agreement.


<P align="left" style="font-size: 10pt; text-indent: 4%">On September&nbsp;4, 2009 we issued 112,500 shares of our common stock, $0.001 par value, to Equinox One Consulting,
LLC (&#147;Equinox One&#148;) for consulting services. We relied on section 4(2) of the Securities Act of 1933 to issue the
common stock and warrant, inasmuch as the common stock was issued to a single private entity which is an accredited
investor that acquired its securities as an investment in a private transaction without any form of general
solicitation or general advertising.


<P align="left" style="font-size: 10pt; text-indent: 4%">On September&nbsp;17, 2009 we sold 195,822 shares of our common stock, $0.001 par value, to Fusion Capital related to
the Purchase Agreement for an aggregate purchase price of $25,000. We also issued to Fusion Capital an additional
6.201 shares of our common stock as a partial settlement of the commitment fee for entering into the Purchase
Agreement.


<P align="left" style="font-size: 10pt; text-indent: 4%">On September&nbsp;22, 2009, GeoVax Labs, Inc., a Delaware corporation, (&#147;GeoVax&#148;) issued 23,141,289 shares of its
Common Stock to Mr.&nbsp;Stavros Papageorgiou. The shares were issued to Mr.&nbsp;Papageorgiou pursuant to his exercise of
Warrant dated May&nbsp;15, 2006. The Company received $1,500,000 for the shares it sold. The Warrant was exercised in full.


<P align="center" style="font-size: 10pt">1

<P align="center" style="font-size: 10pt; display: none">2
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">

<P align="left" style="font-size: 10pt; text-indent: 4%">For each of the aforementioned transactions, the Registrant relied on Section&nbsp;4(2) of the Securities Act of 1993
(the &#147;Securities Act&#148;) and Rule&nbsp;506 of Regulation&nbsp;D under the Securities Act, as amended, to issue its securities to
Fusion Capital, Equinox One and Mr.&nbsp;Papageorgiou. In each case, the shares were only offered to a single accredited
investor who purchased for investment in a transaction that did not involve a general solicitation.


<P align="left" style="font-size: 10pt; text-indent: 4%">As of September&nbsp;22, 2009, the Company has 778,487,547 outstanding shares of Common Stock.


<P align="left" style="font-size: 10pt"><B>Item&nbsp;8.01 Other Events</B>


<P align="left" style="font-size: 10pt; text-indent: 4%">On September&nbsp;21, 2009, the Registrant issued a press release announcing a request for a Pre-IND meeting with the
FDA and submission of a protocol for a proposed Phase 1 human clinical trial for the Registrant&#146;s therapeutic HIV/AIDS
vaccine candidate. A copy of the press release is attached hereto as Exhibit&nbsp;99.1.


<P align="left" style="font-size: 10pt"><B>Item&nbsp;9.01 Financial Statements and Exhibits</B>


<P align="left" style="font-size: 10pt">Exhibit&nbsp;99.1 &nbsp;&nbsp;&nbsp;&nbsp;Press Release


<P align="center" style="font-size: 10pt"><B>SIGNATURES</B>



<P align="left" style="font-size: 10pt; text-indent: 4%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to
be signed on its behalf by the undersigned hereunto duly authorized.


<P align="left" style="margin-left:48%; margin-right:1%; font-size: 10pt"><B>GEOVAX LABS, INC.</B>


<P align="left" style="font-size: 10pt">September&nbsp;22, 2009



<P align="left" style="margin-left:48%; font-size: 10pt; margin-top: -11pt">By:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>/s/ Mark W. Reynolds&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>
<DIV align="left" style="margin-left:53%; font-size: 10pt">Mark W. Reynolds<BR>
Chief Financial Officer
</DIV>



<P align="center" style="font-size: 10pt">2

<P align="center" style="font-size: 10pt; display: none">3




</DIV>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>c90419exv99w1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
<TITLE>Exhibit 99.1</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">

<DIV align="left" style="font-size: 10pt"><IMG src="c90419p90419_01.jpg" alt="(LOGO)">
</DIV>

<P align="right" style="font-size: 10pt; margin-top: -11pt"><B>Exhibit&nbsp;99.1</B>




<P align="left" style="margin-left:48%; font-size: 10pt">Contact:
<BR>
At The Company:
<BR>
Robert McNally
<BR>
404.727.0971 or <U>rmcnally@geovax.com</U>



<P align="left" style="margin-left:48%; font-size: 10pt">At Financial Relations Board:
<BR>
Leslie Loyet
<BR>
Investor Relations
<BR>
312.640.6672 or <U>lloyet@mww.com</U>



<P align="left" style="margin-left:48%; font-size: 10pt">Nikki Snodgrass
<BR>
Media Relations
<BR>
312.640.6732 or <U>nsnodgrass@mww.com</U>


<P align="left" style="font-size: 10pt"><B>FOR IMMEDIATE RELEASE</B>
<BR>
<B>MONDAY, SEPTEMBER 21, 2009</B>


<P align="center" style="font-size: 10pt"><B>GEOVAX LABS REQUESTS PRE-IND MEETING WITH FDA<BR>
Protocol Submitted for Phase 1 Therapeutic HIV/AIDS Vaccine Trial</B>



<P align="left" style="font-size: 10pt"><B>ATLANTA &#151; September&nbsp;21, 2009 &#151; GeoVax Labs, Inc. (OTC BB: GOVX) </B>(the &#147;Company&#148;), an Atlanta-based, biopharmaceutical
company developing human vaccines for diseases caused by HIV-1 (Human Immunodeficiency Virus) and other infectious
agents, today announced that it has requested a pre-Investigational New Drug (IND)&nbsp;meeting with the U.S. Food and Drug
Administration (FDA)&nbsp;to discuss a proposed IND for GeoVax&#146;s therapeutic vaccine as a treatment for individuals infected
with HIV/AIDS.


<P align="left" style="font-size: 10pt">HIV affects the entire globe and comes in a variety of subtypes. Clade B is the predominant subtype in North America,
where there are roughly 60,000 new infections each year. Globally, there are about 2.5&nbsp;million AIDS infections per
year, most primarily involving subtypes AG, B, and C. In 2007, UNAIDS reported 1.3&nbsp;million people living with AIDS in
North America and 33.2&nbsp;million people living with AIDS worldwide.


<P align="left" style="font-size: 10pt">&#147;This pre-IND meeting with the FDA is a significant step toward meeting the needs of those individuals currently
infected with HIV/AIDS. The FDA has 60&nbsp;days from our submission to review our proposal and respond with questions or
comments,&#148; stated Robert McNally, Ph.D., president and chief executive officer. &#147;The need for a HIV/AIDS vaccine is
clear, based on the continued increase of new infections in the United States, despite years of education and
preventative measures. Current costs for oral medications and the numerous side effects of these drugs give further
urgency to the need for a therapeutic vaccine,&#148; noted Dr.&nbsp;McNally.


<P align="left" style="font-size: 10pt">A new IND with the FDA is required since this will be the first time the GeoVax vaccine will be used for a therapeutic
application. The Phase 1 therapeutic protocol stresses safety parameters to minimize any risk to the volunteers. The
protocol, conceived with collaboration from ARCA (AIDS Research Consortium of Atlanta), has specific objectives to
optimize safety while evaluating the ability for the vaccine to elicit protective immune responses in vaccinated participants. The proposed
trial is based on the achievement of excellent post vaccine viral control in animal trials conducted in recently
infected non-human primates at the Yerkes National Primate Research Center, affiliated with Emory University. The
proposed human trial follows the precedents set in the preclinical animal trials and is a critical step towards
developing a therapeutic vaccine for HIV-1 infected humans.

<P align="left" style="font-size: 10pt">Submission of a request to the FDA for a pre-IND meeting is the first step in a process that is expected to take a
number of months to complete. Commencement of the trial is targeted for the first quarter of 2010.



<P align="center" style="font-size: 10pt"><B>MORE</B>




<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt; display: none">1
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">





<P align="left" style="font-size: 10pt"><B>GeoVax Labs, Inc.</B>
<BR>
<B>Add 1</B>




<P align="left" style="font-size: 10pt"><B><I>About GeoVax Labs, Inc.</I></B>
<BR>
GeoVax Labs, Inc. is a biotechnology company, established to develop, manufacture, license and commercialize human
vaccines for diseases caused by HIV-1 (Human Immunodeficiency Virus) and other infectious agents. GeoVax&#146;s AIDS
vaccine technology is the subject of 20 issued or filed patent applications. GeoVax AIDS vaccines are designed for use
in uninfected people to prevent Acquired Immunodeficiency Disease (AIDS), caused by the virus known as HIV-1, should
the person become infected. GeoVax AIDS vaccines also may be effective as a therapeutic treatment (for people already
infected with the HIV-1 virus).


<P align="left" style="font-size: 10pt">GeoVax&#146;s core AIDS vaccine technologies were developed by Dr.&nbsp;Harriet Robinson, Senior V.P. of Research and
Development, through a collaboration of colleagues at Emory University&#146;s Vaccine Center, the National Institutes of
Health (NIH), The Centers for Disease Control and Prevention (CDC)&nbsp;and GeoVax.


<P align="left" style="font-size: 10pt">GeoVax&#146;s AIDS vaccines have moved forward in human clinical trials conducted by the HIV Vaccine Trials Network (HVTN)
based in Seattle, Washington. The HVTN, funded through a cooperative agreement with the National Institutes of Health
(NIH), is the largest worldwide clinical trials program dedicated to the development and testing of AIDS vaccines.
Preclinical work enabling evaluation of GeoVax DNA and MVA vaccines was funded and supported by NIAID, which provided
additional support to GeoVax AIDS vaccine development program with a $17&nbsp;million IPCAVD grant awarded in late 2007.


<P align="left" style="font-size: 10pt"><B><I>Safe Harbor Statement</I></B>
<BR>
<I>All statements in this news release, not statements of historical fact, are forward-looking statements. These
statements are based on expectations and assumptions on the date of this press release and are subject to numerous
risks and uncertainties which could cause actual results to differ materially from those described in the
forward-looking statements. Risks and uncertainties include, but are not limited to, whether: GeoVax can develop and
manufacture these vaccines with the desired characteristics in a timely manner, GeoVax&#146;s vaccines will be safe for
human use, GeoVax&#146;s vaccines will effectively prevent AIDS in humans, vaccines will receive regulatory approvals
necessary to be licensed and marketed, GeoVax raises required capital to complete vaccine development, there is
development of competitive products that may be more effective or easier to use than GeoVax&#146;s products, and other
factors over which GeoVax has no control. GeoVax assumes no obligation to update these forward-looking statements, and
does not intend to do so. Certain matters discussed in this news release are forward-looking statements involving
certain risks and uncertainties including, without limitation, risks detailed in the Company&#146;s Securities and Exchange
Commission filings and reports.</I>


<P align="center" style="font-size: 10pt"><B>###</B>



<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt; display: none">2




</DIV>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>c90419p90419_01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 c90419p90419_01.jpg
M_]C_X``02D9)1@`!``$`8`!@``#__@`?3$5!1"!496-H;F]L;V=I97,@26YC
M+B!6,2XP,0#_VP"$``("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("
M`@("`@,#`@(#`@("`P0#`P,#!`0$`@,$!`0$!`,$!`,!`@("`@("`@("`@,"
M`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`__$`:(```$%`0$!`0$!```````````!`@,$!08'"`D*"P$``P$!
M`0$!`0$!`0````````$"`P0%!@<("0H+$``"`0,#`@0#!04$!````7T!`@,`
M!!$%$B$Q008346$'(G$4,H&1H0@C0K'!%5+1\"0S8G*""0H6%Q@9&B4F)R@I
M*C0U-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H.$A8:'
MB(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7
MV-G:X>+CY.7FY^CIZO'R\_3U]O?X^?H1``(!`@0$`P0'!00$``$"=P`!`@,1
M!`4A,08205$'87$3(C*!"!1"D:&QP0DC,U+P%6)RT0H6)#3A)?$7&!D:)B<H
M*2HU-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H*#A(6&
MAXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76
MU]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_``!$(`#`!#0,!$0`"$0$#$0'_V@`,
M`P$``A$#$0`_`/W\H`*`"@`H`0D`9/`'))X``H`YS4_&/A#1-W]L>*O#FD>6
M</\`VGKFF6&P\<-]JNDVGD=?6NBGA,54M[+#59WVY:<W]UD<U3&82C?VN*HT
MN7?FJ0C;UNU8\\U+]HKX$Z.Q2_\`BUX"B9>HB\1Z==XY(('V.:4$Y!&!WXKI
MAE&9R7-'`U>6]KN+CKV]ZQR3SO**<G&684+I7LIIZ?\`;M_^"<I<_M?_`+-5
MF2LOQ<\-97J(4U6Y')QP;;3G!Y]#6RR'-K)K!2MT]ZFG_P"`\]_P,'Q'DL6U
M]>BK?W*MO*SY+.]U:SUNNYEO^VG^S0H!3XF6<P/>'1O$3@?4C2?K^5:1X=S;
M7_9>6W><%^N_EN9OB?)(_P#,7IY4ZC[]H^73]4+'^VE^S4^1_P`+*M8]N/\`
M6:)XD4<G'!&D'O0^'<V7_,-==U.#2]?>T$N*,DZ8RWK3J+_VS[S2M_VP/V:;
M@A8_BYX;C/I<QZM9X^IN]-C`Y]34_P"K^<)-_49)+^]3O]W/?\"UQ-D5[+,(
M7_PU+>E^2R:ZINZ.T\/_`!_^"?BJ\MM.\._%'P5JE_=OY=K8VVNV0N[B3:S>
M7#;R2))(^U'.T*3A2>@KGJ93F5&#G4P52$%UY=/P.FEG64UIJE2Q]&51[1YK
M/7R=M?+?J><?`'XV^)/C#J?C?7-1/A/1O`=EXCU/0?`%G;O.OB7Q#:Z9<F*;
M7KN2ZU':UAL\M%\BS16F>=-X^S$-V9IEE'`4Z%*DJM7$\L95I6O3@Y*_+[L;
M<TG>T>9N,8W=^;3AR?-<1F-3$5:KHT,)&<H4(K2I42?Q^]*[BHVNU%*4I-*W
M([_4H(P".G4$=,=L5X1]$+0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4
M`%`!0`4`%`&=JVKZ5H.GW.JZWJ5AH^EV4;2W6H:E=P6-E;1J"6>:YN9$CC7`
M/WF%73IU*DXTZ4)5)RT48IMM^26IG5JTJ$)5:U2-*G!7<IM1BO5NR1\)?$W_
M`(*#_"_PC<S:;X'TG4/B)=0@J^J6]S'HOAI).1MBU&Z@EN+W:XP?*M`C=4D8
M<U]-A.%L34498NM'")_82YZGHTFHQ;_Q-I7;6C/D\;QA@Z#E#!T98MQ^VVZ=
M*[[-Q<I+N^5+:S=T>1Z+\>_VV/C=/&GPW\":7X*T2X;Y=>ET&9-.C@DYCD;7
M/%+O'<_*<[K&S=B!N"@$9[YY9P]ER_VNLZLU=\LJEY.W14Z-FMG\;W=KZ7/.
MIYMQ-F<K8+#JA3>TX4TH6;:NZM9M75T[05VE=+H;&O\`[*7Q-U2UN?%'[0?[
M4LNBZ9Q)>BRO;NVTFWDD!58%FU74=.T^`G``2*P.X@A5.<UG2SW#0E&AE64<
MU2R4?<BI6CU]Q3F[7=VY;;R1=;A[%.+Q&=9W[*EJY>_)Q3EO%<\H05[7BE!Z
MK2+T.$TKX0_\$_-.E5M>^-MYXHNX&VS277B)X+>61<B0_P#$HT.-C&QS]VX;
MN0W<=,\9Q1._LLMC1B[V5E)QYO*53>_>/DUT.:GEW",':KFDJTH[N[@FT[W]
MRGMZ2:W:=S[!^%_[//[).M:-8>+/AYX0\+>+-*DEN8K76Y;_`%/7(GGM9?*N
M8)H]1O'0312*0T<L(9<CC##/@8S-<\P]2='%5I8:?+9PY*<;1?5-1T;7VHM-
M]SZ7`Y/P]B*,*^$H0Q-)2?+/GJ2UCHX^]*]D_LM6O9VV/H*R^&?PVTU573_A
M_P""K(+@+]G\+:)`1C(!W)8J3QGG.>37D/'8J2M/%UK=I5)V_%V/8C@,%%WC
M@Z$7W5*FGY:J)N1>&?#4`(@\.Z'`.<^3I.GQ@9YY"6XZYST/6L_K5?;VU2W7
MWY:>JO>[]#3ZMATU_L]/3^Y'_+Y')>-_$/PN^'&F6^L^.9/#?AO2+J^BTZ'4
MM1TJ,67VZ=7:&WFN8;)TMGD6-]IE**2A`)(Q79A:>8XN4H85U:LX1YG&,VFH
M][<RT3M>W==T<N+JY9@(0GBXTJ%.<N12=*\>9K:\8-*_G:]C?/A/P5J4,<Q\
M,>%K^VGB26&1M$TJYBFAF021R1LUJ5='5@P8$@@@]ZY7BL7&;_?U8R@VM9S4
MDUNM6K._G96.B.&PC@N6A2=.2YE:$.5IK1Z*SNNO4^._VQK#P-\/?A7+)X2\
M`^$K7X@>-=4M_!GA6[T7P[I=EKL;ZS!-!J\^G36%HD[3_P!D?:+0,ARK7Z$<
MXKZ'AZKB\5C5[7%5)X:A!U)J4Y2@^5KD3YF[+F]ZRWY+-6/F.)J6"P67\N'P
M=&GBL5/V4'"G&,DFFZDDH1NVX^Y?HYIWN;NF?L1?!S4?!7@C3?%FEZO+XF\/
M>%=,TB[US2M>U/2KIKM6N-1U%H889O(C1M6U"_D7]SNPXR21FLZG$F/AB*[H
M3BJ#J2<(2A%V6D8:JSO&*5M;)[&]+A3+)8;#QKTYNO"E&,IQJ2B^9MSE97<5
M>4I7TU6^HRW_`&.IO"EVM_\`"[X[_%KP1-#EK>SO]4M_%6CJY7:$FTV_6!9X
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M5DU&2OUMJ?8>F:OI>M6,&IZ+J%EJVFW2"2VO],NK>^L[A&`8-#<VTKQR*00?
ME8]:^=J0J4)NG5HU*4X[QE'E:]4[-'TM*I3JPC4HU(U*<MI1DG%^C6AH;O\`
M9;\A_C4<UOLR^XNP;O\`98?A_P#7HYO[K^X+!GV;\J.;^Z_N"P;O]EA^%'-_
M=E]P6#/^RWY?_7HYO[K^X+!N_P!EOR'^-'-_=E]P6#=_LM^0_P`:7-_<DOD%
M@W?[+?D/\:?-_=E]P6#/L?RHYO[K^[_@A8-V/X6_*CF_NR^X+!GV;\J.;^Z_
MN_X(6#=_LM^0_P`:.;^[)?(+!N_V6_(?XTN;^[+[@L&[_9;\A_C3YK?9E]P6
M#/\`LL/P'^-'-;[,ON"PN?8_E1S?W7]P6%J@*&J:C;Z/IFHZM=[Q::787FHW
M/EKND%O96\ES-L7(W/Y<38&1DX%73@ZDX4TTG.2BKZ*[=E?RU(J35*G4J--J
MG&4FEO:*;=O/30_GB^-OQU\:?M`^+H]1U/SK32/.BL_"G@RRNKF33;".5Q%;
MR/"YV7>LW3O&9[ET'SL(X@D<:K7ZCE^`H950=*C\2NZE5QM.;MKK:ZBOLP36
MF]Y-M?C^99EB,UQ'MJONPT5.BI>Y35]-&[<[:]ZHUNEI&-D_U(_9U_8P\'?"
M^SM_$?CVVL/&GCJZ@M9C#J%C!=:'X6D,:326NE6LZR"ZO4ERKW\HR=BB&.)<
MF3X[->(:V(<J.#;P^&BVN:-U.HM5=M6<8M?977XG=V7W.3<-4,%"-;&1CB,3
M)*7*TG3I/1V2U4II[SV=ERI6N_M\810J!415`5=NU411@``8"J`/;Z5\SS2;
MT>^NL7^=_P`]3ZI));62^25C\W?!'@V;]KSXM>,OB%\19;ZY^#_P^\1W7AKP
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MDV=T:V6JHZ=2O%QI^VARQ]IO3<6W92YK<J;4FU9;J_4_L?\`Q#N?%WPM7PEK
M<<T'B_X27[?#WQ+%<.TDDCZ,'@TZ\7<QD$<EK`8"7ZR6$N.,`8<18*.'QJQ%
M.2E1QR]M#W7HWK)::7;:DVM+27SZ.&,;+$9?]5JKEKY<_835UM'2#TVT3CMO
M%V/%_%'C?1/&_P"U==ZOXJU.QT?X7?LM:/=:E?:C>.5M;CQEJT5O:1*R'=ON
MX=0=E@BA5IGDT4JH)?%>GA<)5PV20I8>FY8W.)17+&*5J6K5V[.$?9ZMN\4I
MZM'E8C&4<5Q#.MB:D:>`R*,GS2?_`"]ND[)7YG[5+E22;]GHG?3T^S_;P_9]
MOIKRWM]5\1JUM:7UW;/<>'YK.#55T^&6XFATV>ZN$1[EX89#%'.8#(VV-<R.
MJ-R/AC,HJ#_<^\TG:HVX7M9R2B]-5=QYK;NRU/17%N4WJ)>V]Q-K]U;GM=VC
M[RU=M%+EN]%JSN=0_:B^&6F>%?`OCN\A\51>"?B!<0VFC^*!H8.E:=>RWD]B
M;/Q`RW?G:3,DUK/DO"Z,L3-&[X-<4,BQE2OBJ$)T7B,*WS4^>TI+E4E*FU&T
MHNZ5WK?1I=>JIQ#@Z-#"XJ=#$1PV*TC45.+C"2DXN-1<_-&2:;LHNZV;U/0O
MB=\7?!'PA\*KXO\`%^HR)ID]Q:6NG6VE0?VCJ>L7-XT:P1:18Q2AKX[9%D9D
M.U4(9F`(SR8#`8G'U_JU!)2@GS.7-",.5I/FE9M*^BT;;=CNS#,\+E>'CB,0
MW*,VE"-.TISO_+&Z323NW=)+KJD^B6UT3X@>&(!XB\*F32M8M!*^@^+=,L9;
ME+>YCRHOK`R7,=M<&)^4+^9&3AMK`@)NK@J[5'$6G3?QTI22NM;)VBW9^5GT
MNC11HX_#1]OA+4ZJO[*O"#DD]KQ3FDVM5K==;,^!/B!X&US]B[6(OBU\);V_
MU#X3:KK,%C\0/AGJ=U<7%CI,>J78:/5M`,940+"NZ"%Y%=X"8DE>>&5O)^HP
MF)I<0TG@,;!4\93CS4:T%J^5:\U[^LXIJ,E>22DE?Y'&X6KPQ6CF.7RE++ZD
M^2OAYNZBYNZ<-8]K1>LHNR?,I6/T@LKN&^L[2^MR3!>6T%W`6&UC#<1)-&67
ML=CKD5\?*+C*47O%M/U3L?;QDI1C*.TDFNFC5T6:104`%`!0`4`%`!0`4`%`
M!0`4`%`!0`4`%`!0!#<6\-W!/:W,23VUS#);SP2*&CFAF1HY8I%/#(T;,I!Z
M@D4XMQ:E%\LHM--;IK5/Y"E&,HRC)*49)II[--6:?DT?BE\;/V0OB#\&_%!\
M=?#33+CQAX%TG4H?$]F+(++K/A=-,NEU,6.J6&\RWNFVOD#9=VZS$PQ@S(C`
MEOT'+<[PN/I*AB)+#XF2]G*+TC4YO=;@TK*4D[<CM9NT;JQ^8YIP_C,LK/$8
M2$L1A:;YXRC\=+EUM4C>[C&VLU>Z5Y6>A^H_P4^.W@3XY^'1J_A+4%75;&&U
M'B/PW<MY6JZ#>SQ`M'-$>9K-I4E6&[CS%*$/*N"B_%YGEF)RVJH58MTY-^SJ
M+2,TNM[>[)+>,K6?R9]YE>;83-*//0GRU8)>TI/24'L]/M1O?EFKI^3T/9F4
M,K(>`RLK8;.`P*DGUX(P*\V+2:?2+OO?[^G:R^9Z;5TUM=-?>?!7[(7BFW\!
M^)?B=^S=XF\O3/%OAOQIX@\1Z`DSE?\`A(=%UB;[:\]F6P)&BM/L=T$!9FAO
M"XXB?;]=G]"6*HX3-Z*<J56E&-3KR-?#?KNY1?:22ZJ_QO#5>."K8S)*UJ56
MC6G*DOYXOXK:6O9*:[QDVMF=A=_L-?!O5;R]U36]2^(FI:QJ=W=:AJ=__P`)
MOJUJ+F^OIY+FXFCM8F\NWC\V1@D2Y"*%7G&3R_ZSYA32IT51I4J:2A#D7NI:
M+73RN[*_8ZWPCE4Y2J5G6JU9MN4G4:O)N[=M;?>SX.\)/<7O@KX6_#KQ)=WL
MGPHU+]JSQ!HGB*;4-0N98)8-+_L'^Q_#][-)*'^Q7'GWDS#<J+)NFVAE!'U6
M(A&,\3C*6N8QR^+BHJSM)U^>HM'=KEC'FNG:T$E>Z^.PC;IX3!5)2CEDLSDJ
MC>D$XK#J%.ZM92YIR:VYKU+]#[7_`&@IXDLM7^#OA/\`9=OOB'H#^%8XWUOP
MW::+I.G>&M2U6.\33(],`LQ(E_9FV@O'>&2(@/$IR)#N^9RO_EWC<1G/U::J
M6]G4YY<\(N-^:\K<LM8VL[6OO8^MSCX:N78;(7BJ3I?Q:?+!4Y2YN7DM!OF@
M_>W5[ZZ-W^8='\/^+-0\8?L;?"_]H"UU&#2H++Q?=-H'B29)QJ.J6NJZFGAK
M3]6B6219)!9V^AVJ03.Q$-RL)P)F4^U*M1IX?/,;ECC*I>G:<%;E7LX\\H[+
M1RG.]K<RONCP(8>O/%<.X'-H3A2BJO[NIU;J34(R2;W2IPUDWRM+:1]F?M;>
M`_AG<?`OQAJ6NZ5HFB77AC2Y-1\(ZQ:VMMIM]IOB*W4KI%MITUJD4G^D7)2'
M[.I*.'!VYC5E^>R'%XW^TZ%*G4G4C4?+4C)R:=-7<FT]DMU+_.S^FXCP>`65
M8FK4I4Z-2DKTIQC&,O:?9C%QLWS?#;Y]#Y9TKQE<_LV^*/"_Q?\`$B7JZ%\>
MO@K:ZGX@MU0R,/BAH.BV-[;RRQH"Q?4C<12O.V,/J]W(WRH<^Y5PU/.*-;`T
M;4YY9B^6+YK?N)2E=;7O%)Q44]>2*W9\]2Q$\CK4,QJ\\X9K@N:22M;$QC%Q
MNMG=V?,[?Q)2U6_(^'/AC:VX_9>MOB;"KZ?\=?'OBCXA?$+[=)*;?7=7GLS?
M>!-#U1_-`>+R-0_U>0/,U:8-G))Z*F-DUG"P:7/EM&%&CRNSA%7]M*$7V:5]
M'?D6NIA1R^G!9&L=+EI9IB*E>O>+2G)I>PC.2ZRYG?5)>UD^B/O/]I3P#\.;
MCX"^/X]8T+0=,LO#WA74-0T*Z@TZSLWT?5["V)T,Z=)!$C6SR7XM;8)&0'6X
M,9!5L'YC)\5C5F6&C3J3J.K/EG%RDU*$M:C=[VLKS<MU:]T?79Y@L#_96*<Z
M-.DJ-/FIRC"*<)K2FHVMNVH);/FM9GG7P#T'P=XF_8JT+2/B`MJOA"X\*^*)
MM=N+OB/3K2UUS6KQM3CD'S0W-DT*W,4B?,LENC+S@'IS&IB*/$$Y8.\J_/34
M%%?$Y0@N1QZJ5[-/='-EE'"U.&H0QK4<-[.K*<FU[D5.<N=/I*.Z:V:ZGQ3^
MS%-X?\4_&3X=Z%\2_%6MZYX6\(0:O!\`[/Q!I,EKH_B":#5+TQ7+>9.1;7%O
M/:J\%O*;D&:UBM?,`M8XV^BS=5:&`QD\'1A"M5Y7BG"3YXKEC=V2L[1TDURI
M1ESI>\V?*9)["KF6!I8VO.5"ASK!QJPM&3YVX):^Y>2YK>]><53O9)'[9U^=
M'ZD>2?$?PA=?%+3H_!4OF:;X.N=2TZZ\6WDT2F77]+TZ\CNY?"^G6S[9([>_
M>&-+C4"4$<.Y8!*\A,7HX'$0R^3Q6E3$<DHTH=*<IJWM9-:7BG+EANW9RLM_
M*S#"U,QC'!ZTL)SPE7FTOWL8N[H0B]4I-)3J.R4=(\S>GK$<<<,<<42+'%$B
MQQQH`J)&BA415'"JJ@``=`*\]MMMO=GJ))))*R6B79+8?2&%`!0`4`%`!0`4
M`%`!0`4`%`!0`4`%`!0`4`(>!QC/;/`H`CQ@8)X/!W8P?4#`Y'UK*[6J?*^]
M]+];?=UUZ)H?R/'O$'P%^%VNZLOB*+P\WA?Q5'DQ^*/`U]?>#=?RS^8QN+O0
M9K9;]3*%<I>QW*,R@LIYSZ=+-L93A[!UO;4M+TJT55AVVFFXJVFC6FFQY=?)
MLOK5%65'ZM76U6A)T*G5_%3:O=N[33N]6:^GZ'\2/#]S!';^+M/\9Z(H=7M_
M%>G1:9XBC1$"P"#7M`@CM;J3@[WN=+WMU\P$FB<\OJJ7-AY8.LWHZ+YJ>N]Z
M=1\Z=KVY:FG;LH4<SPTH*GBH8RA%>]&O'DK:)VY:M)*#;=KN=+YG"?%/X`>"
M_C.VGZGXBTK6?!_C/2@G]E>./".IP67B"S"KM^SOJ5M\U]:*"`J7,.4Y\HQY
M;=T8+,Z^6-PHSAB<-+1TJBERM:WT=G%OKRMI]4V<V-RFAFG+/$8>>#Q45[M:
ME.#E%_XHN\DNG-%6OI;4\<'[,?[0-IFVTW]K3QW'80DI:+>6KW-TD`)$8FF:
M\/F2!<9.<<=*]59UDMO>R.',]6U[%*][NUZ+T>K/)?#^>)OEXAJQALE>LK+I
MM5WM:]CJ?`?[).D:5\)_%?PE^(6O#QGIGB+Q9/XRM=:L;.30]<TC7+FWM(I-
M0M+G[1<*E['/9K*DH4`BYGCE1XWP>?&9\YXW#8W!4I8>5"DZ3A4DIQE'FE)*
MT8PLO>?I:/+:QU8'AM4LOQ67XZM&O#$556C.E&5.<)*,(MWE*>ON)_WKRYD[
MG-K^S%\=-)']G>&?VK/'-EH-J%BTVWU.S74-0@MU"A8[B[:Y7SF7&T$!1MQP
M.<[QSK)Y1C+$9'"5=_&X<D(-Z[+ENOG=^9A+(,YIMPPN?U84(_`I\\II6T3?
M/;YJU^QV[_LS7/C/P%#X2^-7CO4?'GB#0]9N=8\&?$/3X6\/^+O#,ES'#^ZB
MO(I9$NDCN(%<"5"&78K#=#$Z<D\ZHX;%>WRS"K"4)Q4:U";4J=2S=G9*/*^5
MVNK:Z]7?KCD-7$X3ZOFN,>+K4IN=#$0CR5J5TN:-WS7BVD[/?:^D;<GI_P"Q
MYJ&O:C8GXT?&;QY\6/#>A7D-WH?A34KMK'2I)(&^237`DDCZ@QC4(RHT6X/(
M"VUMM;U,_HT(/^R\OIX&K4C:<^6-]5KR**BMVW[U[.VC.:EPS6K5%_:V95,?
M0I.].E>277XW*4NED^11NF]M#VOXY?`SP[\;/"&C>$M2==*AT+Q#HFL6%S:V
MZ;K:TL)5@U'3+=%VB&&[TA[FU&W`0M$^#Y0!\W*\RGEV(JU[.:J4YQ:5KN33
M<)/F37NU+-Z7<;KK<]?-LIIYGAJ.'YE1]A4IRBTOA@FE.*2:^*G>*Z1=G9VL
M;7Q/^#7@7XM>#8/!'B>PN(-+TZ2TGT.\TBX&GZIX>N[&'R+2YTB["/\`9W2`
MF$QLDD;HQ5U)"E<,'F6*R_$O$497E4OSJ23A/F=_>5T[WU35K-]KFV/RK!YA
MAHX6O3Y84[.FX>[*G967([-)./NM6LUIV:^:IOV-/$/B6*;0?B-^T#\2_&/@
M:U20:'X;ENEMVBECBDBTRXU>XE>9-1:S+)(%$4>]HP"57BO<?$.&I*%3!Y51
MP^)?\6I:.J=N91Y8Q<>;5:MVW[H^?7"^*JN5+'9Q7Q&#C_#IIR335U!RYISB
MU%/6RN]=4K6V/^&8?&TOPG\,?`ZX^)UE9_#W2;]SK\FD>'[FT\2^*=%;6IM7
M_LBYOY-4DM[&(^=L?RK<B0Q1L^4#1O+SG+XXNMF-/!5OKDXVASU8.E3ERJ-^
M54U-Z)J_.FDW9WU-8Y%F7U*AED\=16`IR]_DI5(UJD.=SY7)U7%;K:-FTKIK
MW7ZCX^_9K^&?C7PCX6\*6EC/X,?P"]F_@;7_``JR66N>%?LUS!=.FGW4R2"1
M+AX-THF$I:1C-GS?F/F87.,7A<16K-^W6(3]K"?P3TLKK39:)+[*L]+'IXS(
ML%BL-AZ$8O#2PEO85:5E4IJZ;2;O\35W?7F]Y:GKVA>&8]%MX([C6->\0W4`
M7&H^(-0%W=,P4#?Y5K!;6D;'&28K9.:XZV(=5OEHTL/'^6E#E6GFW*3^<F>A
MA\*L.E>O5Q$E]JK.[_\``8J,%\HGQCI7Q5\97D?B#PMJ7CB729/AU\5_B!K7
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MXSA74:L_:SK1@]:,%&\:7M'&*E42;C>2O8;H_P`;?%NBMHVG7'AJ*]\+:/XV
M\+?#'6=?U/7[K4_%=[J]]X*T[6-8EM[=+7.IWVEZI<7*W<TGEB:*WD,2&0-M
M=7*L+5]K.G7<<35I5,13HPA&-.,57E""<KI0C.'*XK>+4G*RLB:6<8RA[*,\
M*GA*%6EAZU:=2<JO.\/&I4:C9N<J<^92>JFG'DN[D>C?M&>/->TKQ'XAT;X7
M7>I>'Y/#6I>(_!5[;QZK;[5L=6BTN+3_`!*][;117FH75F]QJ\<&B/<OY&G7
M5I\UTHRZN1X6A4H4JN.49JI&G6BG3;NX<TO9*,FTHR_=<U2T6Y1G\#U=+/\`
M%U:6(K4LO<J7LG5H2M.*24^5*LY+E;<'[7EI-R2C.%N=67I;^+?&'C+X$S>*
M?!>N>#G\9Z_H-U+X6UC2+FXA\,7=^]S+%:?V?)XHM8I;>YD@B>-4OX,0W61*
MK)&<^>L-AL+FL</B*-;ZM1G%5822]JERIRO[)R3CS.]X-MPU6K/1^LXO$Y-+
M$X:K06+K4Y.C.FVJ3E=J/*ZR@U)I6M-+EGHTTCP_0OV@;Z/P_HEI\.+'QCXT
MUO5H?%6OZM;_`!'^V:MJ&D)X2U*W\/ZMX9T^Y\(:8Z75W<:PDR6UT2UE%EI)
MIE21(E]6630E5JO&2I86G3Y(0="T%+VK<U4FJLK1C&#LXKWW964K.3\6&>U*
M=&C'!0K8JK456I-8F\Y1]DU3=*G[""YG*HG:;7)'5R:NDNQU;]H/QA'-XPUO
M1O!VCMX$\`>(O#/AOQ7?ZOJ=S::Y8ZAJL>@-XCB6UC3[,JZ!_:\YNI7F"MY"
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M?A'_`(2C3->U#07M_%'C_P"(7BS0/"FAZIJE]HYD&GPAGUFZ6VD:UD2.%F>+
MBO4EEN`J4Z[IRIN.)Q=10G2ISC*E2H4ZE6I3IQF]](KFCSQDWRW6AX\,US"C
M5H*I&K"6$P=)SIUITVJU?$5:=*G4J2IIM+WW+EDX2BE=QW/5?$_[16I6WB6^
M\+>#M#T/6KO_`(3#6_"^DZA?ZK);:0]OX2\`VOB_QAK-_=6JR&*TTR]O[6Q<
M1*[%HYEP&P1Y^'R?#NA3KXJM5I+V4*DHQ@G*]6LZ=*$4VKN48N5Y6NVK729Z
M6*SVO#$5</@Z%&JU6G3A*<Y*%J.'C6K3FXQ=E"<N3W;VY97U*?A_]H_7M0L[
MBX\0>&=&\)2ZSX`\(>*?!%M>:A?ZG=WFM>,-0OM#T?0]7L-,M)+@RZGJ5FUS
M8QV*32-9Y:8H^=EU<CHP<%1K5*ZI5ZM/$64(J,*<8SE.$F^7W(RY)\UE[1J,
M>SBCQ!6DI^WH4\*ZN'I5<,I.<I2J5)2IPA.$8\W[V47.FH*_LDY2>[63H7[2
MGCCQ+HD(T?P9X<_X2*RL?BI>:_)J&K:AI_AVTM/AK=Z9IIUFU<V\EY_9U[J5
M[<6X@DC\U7LY`7`1FJYY)A*%1^UQ-6-%RPT:?+",IRG7C*3A9N,;I)-2T5FF
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MYK5KXI8&=*G]:HU:D<0J<I.-.E&%X5%S)/\`>SE",5T3;>Q]`5XQ[@A'&!_A
M0`S!'8YXR1MY]B3VQ[5GRM='\K7^]_?W??35_@!4CC''H,`=NQ(Q^!_G1RM*
MUKKLK+MTTM\G\F`NT_CSR."!STR>/Z4^62[?*ZTZK?2_3MW`7#>H'MCV'O3M
M);2Y5VMM\[B##?WA_P!\_P#UZ+2_F_#_`((!AO[P_P"^?_KT6E_-;Y?\$!,-
MGICG(Z$=,>Q__7[4/FT5N6W7?OKTZ>NK\KCT_K0,-TZ#KQU^F30T[=GV7Z7_
M`!T`-OL/^^F'Z"IY'V_\FDOP7D`;?^`\]F)S^)''7M3C&R?V?23?Y[;]/(`P
M?0<=,]OIQ^O7BERR[+3J_P!+?=?=]0%`(XXQ[<8_^OZ_A5QNE9K;MMZ:N]P!
M@>,9XSTQW]B<4/9VW\K?KH+\!-I&,9^G``S_`"Z]LU-I);MOMHK?=MYVN^P_
MP%`(XQQU'/3/:K6W9^7](1QP^'?@9/\`A+=OA/0@?';;_&7_`!+X/^*E?RI(
M0VKY7_3"(Y9`"^<;R1R<UU?7<7_L]L1-?5/X/O->RUN^3M>VO<Y%@<&OK/\`
MLU/_`&O^/[J_>[_'??=V[7,";X)?"6YT6X\.S_#SPM)HEWJD&N7&GMI<!AFU
MFVMH[*'5'.-_]H"UB2(S[M[("&8[CG99KF,:RQ"QE55HQY5/FUY6^;E[6OK;
MH]C!Y-E7L7AW@*/L)2YW#D7+SI<O-;ORZ-]5HR:]^#7PKO\`4-1U:[\`^&)]
M1U?3;72-4NVTN!9=0TRQ^R?9+.[*!1-#$MA9*NX$A;:-<[5`J8YGF$(1I1Q=
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M>#7T;Q#X??PSI#Z)XLO-0U#Q-I36D;6>N7NK&/\`M&[U&)ABYGN/*B\QFZ[`
M.PK/ZWB55HUO;257#J,:<KZP4?A4>B2OIH;/!81T:U!X>'L<0Y2J1M93E)IR
M<K;MVU9'JOP[\#ZV$75O"NBWZ1Z=IFCHES91NB:5HVH1ZMI6GHF`%M+74X8;
MF.(`*LD2MCY1APQF+I7Y,1.+<IS=GO.I%QG)^<HNS?5"J8'!U$E4PT)*,(4T
MG'10A+GA%+HHR5X]CE?&_P`'O#WBVQO;6T@T?0Y]6\00>)=<NI/"V@Z__;&K
MVEB=/M-0NH=9MI5%_;VVQ(KA2K*J&,AHG9&WPF95L+*$FYU%2@Z=-1JSI.$7
M)2E%.FT^63W7G?1G)C,IP^*C.,5"E[:?M*MZ-.K[22@X1;51-*44]&O1W3:-
MW0?AEX1T'P#I/PV.G)JWAC2;>UB%IJZ177VR>UU!=86\O$6-(FN&U=1=X2-$
M63&Q%55485L97K8JIC'+DK5&W>-U:ZY;+K;ETU>JW.FA@,-A\'2P$8<V'I14
M5&5G>SYKNUE?F][1))[)(T=8\`^"_$$?B&+6_#.D:I'XLMM+M/$BWMI',-9M
MM$>272(K[</WJV<LLCP=#&SEE(8YJ:6+Q-!T72K3IO#N3I\KMR.?Q-6_FV?=
M:;%U<'A:JKQJT(3CBE%55)74U#X%+_#=\O9ZK4R['X3?#33%MTT[P/X;L4M(
M=<M[6.UTRW@CMX?$UI!8>((X4C4+&-0LK:"&?`!D2)5/%:SS''5&W4Q52;ER
M7YI-M^SDYPO?^63<EV9E3RS+Z*BJ6#I4U'GLHQ44O:Q4*EK6MSQ2C+ND6[[X
M:^`=2M9K*^\(Z%=6L]AH6ER0S6$3`:?X8DEE\/6L9QNABT^2>9K<1E3&96VG
MYC2IYAC:4E.EB:E.2E.=U)KWJG\23[N=E>^]EV'4RW`58.%3"4I1Y:<+.*TC
M2O[.*ZI0N^6UK78S3OAE\/\`1[>>STOP=X?T^TN=+U30Y[>ST^&WBDT?7+MM
M0U?3FCC50+2\OG>::,#$CD,V2.%+'8R<E.>(G*49QJ)MZ\\%:,O\45HGV"GE
MV!HP=*EAH0IRA.FTE;W*CYIP7:,GJTK*^I%>?"KX<7]AJVEWO@KP[<Z?KEWI
M5_JUI/IL$D-]>Z':6]AHUU.K+S/96=I;00,I4QQPJJD"G',,;"=.I#$U(U*/
M,H24K./.^:>J_FD[N][L4LLP$J=6E+"4I4ZK@YQ<4XR<$HP=MO=BK1M:R*?@
M7X8Z5X+UCQ9XIDO;C7?&'C>ZLIO$7B.]M[.SFN+32+<V6AZ5:66GPQ6]CI]C
M8[8U2-=TK[Y9G=V^5XK&RQ,*%%05&AADU""<I:RLYRE*3;<I-7Z);)+6\8++
FJ>"J8FO[25;$XJ2=2I)1CI%-0A&,%&,8P6FUWO)M[>F5Q'HG_]D_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
